Biden’s Alzheimer’s Lapse
September 29, 2022 No Comments
His Administration increased Part B premiums by 14.5% this year and blamed the increase on expected high demand for Biogen’s Alzheimer’s drug Aduhelm, which the Food and Drug Administration approved last summer.
